Provider P34-18 Clarification to MAPD PA Requirements for Hereditary Angioedema (HAE) Medical Drugs Read More
Provider P35-17 Addition of Drug to the Substance Reduction Therapy Prior Authorization with Quantity Limit Program Read More
Provider P11-17 Pre-Admission Notification Requirement for Admissions Effective June 1, 2017 Read More
Provider P1-18 New Drugs, Aimovig (erenumab), Fremanezumab and Galcanezumab Will Require PA Read More
Provider P25-17 Addition of New Drugs to the Hepatitis C Second Generation Antivirals Prior Authorization (PA) with Quantity Limit (QL) Program Read More
Provider P72-17 New Availity Functionality Available to Create and Submit an Electronic Referral Read More
